US20170112834A1 - Ceritinib formulation - Google Patents

Ceritinib formulation Download PDF

Info

Publication number
US20170112834A1
US20170112834A1 US15/313,367 US201515313367A US2017112834A1 US 20170112834 A1 US20170112834 A1 US 20170112834A1 US 201515313367 A US201515313367 A US 201515313367A US 2017112834 A1 US2017112834 A1 US 2017112834A1
Authority
US
United States
Prior art keywords
tablet
ceritinib
pharmaceutical composition
binder
weight percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/313,367
Other languages
English (en)
Inventor
Sebastien Breulles
Simon ENSSLIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20170112834(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to US15/313,367 priority Critical patent/US20170112834A1/en
Assigned to NOVARTIS PHARMA AG reassignment NOVARTIS PHARMA AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BREULLES, SEBASTIAN, ENSSLIN, SIMON
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS PHARMA AG
Publication of US20170112834A1 publication Critical patent/US20170112834A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present disclosure relates to a new pharmaceutical composition comprising Ceritinib. It further relates to a tablet comprising Ceritinib and a process of preparing said tablet. In addition, the disclosure also related to a use of the pharmaceutical composition or the tablet.
  • WO2008/073687 A1 disclosed ceritinib (also named LDK378) as compound 66 in Example 7.
  • Chemical formula of ceritinib is 5-chloro-N 2 -(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N 4 -[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine.
  • Ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor.
  • ALK is a member of the insulin receptor superfamily of receptor tyrosine kinases. Genetic alterations of ALK have been implicated in oncogenesis in hematopoietic and non-hematopoietic tumours. The gene has been found to be rearranged, mutated, or amplified in a series of tumours, including non-small cell lung cancer.
  • Ceritinib has been approved by the US FDA as Zykadia® for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
  • ALK anaplastic lymphoma kinase
  • NSCLC metastatic non-small cell lung cancer
  • the approved dosage is a daily dose of 750 mg administered orally, with possible dose reduction in 150 mg increment(s) to 600 mg and 450 mg as needed.
  • the minimum treatment dose is 300 mg.
  • the approved dosage form is a capsule of size 00 containing a 150 mg dose of ceritinib.
  • Ceritinib is a difficult compound to formulate. In water, it exhibits solubility of only 0.02 mg/mL (at 25° C.), and together with its low permeability according to the Biopharmaceutics Classification System qualifies for a class IV compound. In addition, physical characteristics of Ceritinib cause sticking and picking during tableting or encapsulation of the drug and make it poorly compressible. Furthermore, the drug is administered at a high dose of 750 mg, which would require a patient to take daily up to 5 units of 150 mg. If the dose is to be increased in a respective dosage form, the increase in drug load generally negatively affects the compressibility of a tablet. Ceritinib's sticky nature causes a high drug load to further negatively influence the manufacturing of tablets due to enhanced sticking/picking.
  • a high drug load of more than 40 weight percent, preferably more than 45 wt %, more preferably more than 50 wt %, particularly 60 wt % of Ceritinib in a tablet can be achieved by using a specifically adapted wet granulation process, whereby solely the pharmaceutical active ingredient ceritinib is granulated with a binder.
  • Said wet granulation process also leads to high compressibility and much reduced or even no sticking and picking during manufacturing.
  • the latter can be further improved by adding the right amount of a lubricant, such as for example magnesium stearate.
  • the tablet obtained by employing the disclosed process exhibits suitable hardness and reduced friability.
  • the table can comprise for example 70% by weight of the drug substance.
  • the tablet can be thus of an acceptable size that is more convenient for patients to swallow, even if containing doses up to 375 mg or more.
  • the in vitro dissolution profiles predict that the tablet can also behave in vivo comparably to capsule.
  • the compliance of taking the new formulation is expected to be much improved compared to the one of a capsule given the high daily dose that needs to be administered and inconvenient size of a capsule.
  • one aspect of the present disclosure is a pharmaceutical composition comprising more than 40 and up to 70 weight percent of Ceritinib based on the total weight of the pharmaceutical composition. Further the disclosure provides a tablet comprising Ceritinib obtainable by preparing granules comprising Ceritinib and a binder by wet granulation, mixing the granules with at least one pharmaceutical excipient to obtain a mixture, and compressing the mixture in the tablet.
  • the pharmaceutical composition and the tablet according to the present disclosure can be used as a medicine.
  • Another aspect of the disclosure is a process of preparing a tablet comprising Ceritinib, wherein the process comprises wet granulation of Ceritinib and a binder, and a compression step.
  • high drug load denotes more than 40 and up to 70 weight percent of Ceritinib based on the total weight of a composition or a dosage form core, e.g. of an uncoated tablet. In one embodiment, it denotes 50 and up to 70 weight percent of Ceritinib based on the total weight of a composition or a dosage form core, or at least 55 and up to 65 weight percent of Ceritinib based on the total weight of a composition or a dosage form core. In one embodiment the “high drug load” is used to mean about 60 weight percent, specifically 60 weight percent of the drug based on the total weight of a composition or a dosage form core.
  • Ceritinib mass in a tablet can be for example 150 mg or up to 1000 mg, preferably between 150 mg and 750 mg.
  • Specific Ceritinib doses in high drug load pharmaceutical formulations are respectively and independently from one another 150 mg, 300 mg and 375 mg of ceritinib.
  • treatment comprises a treatment relieving, reducing or alleviating at least one symptom in a subject, increasing progression-free survival, overall survival, extending duration of response or delaying progression of a disease.
  • treatment can be the diminishment of one or several symptoms of a disorder or complete eradication of a disorder, such as cancer.
  • the term “treatment” also denotes to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease in a patient, e.g., a mammal, particularly the patient is a human.
  • terapéuticaally effective amount of a therapeutic agent is an amount sufficient to provide an observable improvement over the baseline clinically observable signs and symptoms of the disorder treated with the therapeutic agent, i.e. ceritinib.
  • the therapeutically effective amount will be administered to a patient in need thereof.
  • FIG. 1 The figure show the tablet hardness versus the applied compression force of compositions described in examples 3B to 6.
  • FIG. 2 Dissolution profile (pH 1) of a tablet described in Examples 10 and 11 versus capsule (Zykadia®) formulation.
  • FIG. 3 Dissolution profile (pH 2) of a tablet described in Examples 10, 11 and 12 versus capsule (Zykadia®) formulation.
  • FIG. 4 Dissolution profile (pH 4.5) of a tablet described in Examples 10 and 11 versus capsule (Zykadia®) formulation.
  • FIG. 5 Dissolution profile (pH 6.8) of a tablet described in Examples 10 and 11 versus capsule (Zykadia®) formulation.
  • a pharmaceutical composition comprising more than 40 and up to 70 weight percent of Ceritinib based on the total weight of the pharmaceutical composition, or weight percent of Ceritinib based on the total weight of the pharmaceutical composition was easily obtained.
  • Other drug loads such as at least 45 and up to 70, 50 and up to 70, at least 55 and up to 65, or particularly 60 weight percent of Ceritinib based on the total weight of the pharmaceutical composition, can also be prepared.
  • weight of the capsule shell is included in the total weight of the pharmaceutical composition.
  • the pharmaceutical composition is a coated tablet, only the tablet core should be taken into account, i.e. the total weight of the pharmaceutical composition is the uncoated tablet.
  • ceritinib drug substance can be wet granulated using one pharmaceutically acceptable excipient, a binder, which can be added to the drug substance in a dissolved state (e.g. in an aqueous solution) or in a powder form and then granulated by adding a granulation liquid.
  • a binder which can be added to the drug substance in a dissolved state (e.g. in an aqueous solution) or in a powder form and then granulated by adding a granulation liquid.
  • a combination of more than one binder can be used.
  • the wet granulation can be performed using a standard high shear granulator to form drug wet granules.
  • the solvents used for wet granulation can be for example water, or low alkyl alcohols like ethanol, propanol, isopropanol, ethers, or mixtures thereof.
  • the wet granules comprising Ceritinib and the binder are subsequently dried.
  • the material can be dried by using for example a fluid bed drier. Removing substantially all granulation liquid can be advantageous in terms of reducing unnecessary stickiness of the granulation mass due to the remaining granulation liquid.
  • the obtained granules can be also calibrated, which can be achieved by a sieving method or the like, for example by using an oscillating sieve.
  • the binder used for wet granulation of the active ingredient can be a polymer that is otherwise suitable pharmaceutically acceptable binder or a coating polymer.
  • Particularly suitable binders are for example starches, such as for example potato, wheat or corn starch, Hypromellose (named also Hydroxypropylmethyl cellulose), Hydroxypropyl cellulose, Hydroxy ethyl cellulose, Povidone (named also Polyvinylpyrrolidone), Copovidone (also named copolyvidone), Gelatine and Polymethacrylates.
  • the binder is povidone.
  • Povidone By specifically selecting Povidone as a binder the friability of the final tablet can be further improved.
  • the overall characteristics of the pharmaceutical composition are further enhanced, if the drug-binder granules form an inner phase, and additional pharmaceutically acceptable excipients are added to the blend as an outer phase. This way, the stickiness of the composition can be further reduced.
  • the composition can contain further pharmaceutical excipients, which can be in the outer phase, or elsewhere, and can be pharmaceutically acceptable excipients such as filler, disintegrant, glidant, and/or lubricant, or mixture thereof. Further excipients like antioxidants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof can also be added.
  • the composition can comprise one or more fillers, for example a microcrystalline cellulose, silicified microcrystalline cellulose, lactose (anhydrous, monohydrate), starch, mannitol, sorbitol, calcium phosphate (dibasic anhydrous, dibasic hydrate, tribasic), isomalt, sucrose, Hydroxypropyl Cellulose Low-substituted; one or more disintegrants, for example Croscarmellose Sodium, Crospovidone, Sodium starch glycolate, microcristalline cellulose, silicified microcrystalline cellulose, Hydroxypropyl Cellulose Low-substituted, cellulose powdered; further binders, such as for example starch, Hydroxypropyl Cellulose Low-substituted, Hypromellose (Hydroxypropylmethyl cellulose), Hydroxypropyl cellulose, Hydroxy ethyl cellulose, Povidone (Polyvinylpyrrolidone), Copovidone (Copolyvid
  • Excipients in a dry powder form or “dry excipient” mean herein that an excipient is substantially free of water or moisture, preferably the excipient is dry. Using only dry excipients in the outer phase normally does not worsen the sticking and picking problem and can even improve it.
  • excipients can act as a binder, filler and/or a disintegrant, depending on their content in the blend, coexisting excipients and how and when they are formulated in the formulation. It is completely in the purview of a pharmaceutical technologist to understand the role of a pharmaceutical excipient in the composition. He will be able to assess the role of the excipient in the pharmaceutical composition or the dosage form based on the characteristics he wants to achieve, such as volume, hardness, dissolution profile etc, of a pharmaceutical composition or a dosage form.
  • the outer phase comprising one or more pharmaceutically acceptable excipients is mixed with the inner phase (granulate) using e.g. a free fall mixer.
  • the outer phase comprises Cellulose Microcristalline as filler, Hydroxypropyl Cellulose Low-substituted as dry binder and Croscarmellose Sodium as disintegrant.
  • the formulation may also contain one glidant, most preferably colloidal silicon dioxide.
  • Hydroxypropyl cellulose low substituted in the outer phase further helps reduce friability of the tablets obtained from the pharmaceutical composition.
  • the content of Hydroxypropyl cellulose low substituted in the outer phase can be around 5 wt % based on the on the total weight of the pharmaceutical composition.
  • Hydroxypropyl cellulose low substituted differs from Hydroxypropylmethyl cellulose (HPMC, hypromellose) or even plain Hydroxypropyl cellulose (HPC).
  • HPMC Hydroxypropylmethyl cellulose
  • HPC plain Hydroxypropyl cellulose
  • HPMC Hydroxypropylmethyl cellulose
  • HPC plain Hydroxypropyl cellulose
  • Friability can be measured by a friability test as described in the 8 th Edition of European Pharmacopoeia (version 8.1) by using the tablet friability apparatus.
  • the friability of uncoated tablet cores is measured, as coated tablets normally do not show any friability.
  • the method measures weight loss of tablets after mechanical stress has been applied to them.
  • a drum of predefined measurements is rotated 100 times with 10 tablets (depending on the tablet mass) that have been carefully dedusted and accurately weighted before the testing. After rotations, the tablets are cleaned of any loose dust and again weighted. Maximum loss of mass not greater than 1% is considered acceptable.
  • the prescribed test for friability of uncoated tablets of Eu. Ph. Ed. 8 (8.1) defines additional specifics.
  • a lubricant preferably magnesium stearate
  • the amount of the lubricant in the pharmaceutical composition can be at least 0.5 and up to 3 weight percent, preferably at least 1 and up to 2 weight percent, particularly 1.5 weight percent based on the total weight of the pharmaceutical composition.
  • the lubricant is preferably magnesium stearate.
  • it instead of increasing the amount of the lubricant to the pharmaceutical composition, it can be sprayed and deposited on the material contacting surfaces of pressing tools, e.g. punches and/or dies of the tableting machine before compression.
  • the amount of lubricant impacts the compressibility, hardness, friability and dissolution profile of the final dosage form, i.e. tablet. Higher is the amount of a lubricant, lower are the compressibility and hardness, but friability increases.
  • the lubricant reduces sticking of the blend, but does not influence the dissolution to the extent that would change the bioequivalence remains the same.
  • the pharmaceutical composition is then processed to prepare a final dosage form—a tablet.
  • a final dosage form a tablet.
  • This can be achieved by compressing the final blend for example on a rotary tablet press.
  • Tablet of different shapes can be prepared (round, ovaloid, or other suitable shape).
  • the pharmaceutical formulation or the tablet can have further layers and coatings.
  • One possible coating can be for example a colour coating.
  • the shape, the final mass and the drug load dictate the dosage strength of the tablet.
  • the tablet can contain for example a 150 mg dose of ceritinib. Given the high drug load, the tablet of the present disclosure can contain at least 150 and up to 750 mg, preferably is at least 300 mg and up to 375 mg.
  • the tablet can have 300 mg Ceritinib. In one specific embodiment, which is preferred, the Ceritinib dose in the tablet is 375 mg. Increasing the dose in a single unit dosage form reduces the daily pill burden compared to the approved capsule formulation dosing regimen.
  • the tablet of 150 mg strength has a hardness of at least 45 N, but preferably has at least 50 N.
  • tablets are placed between the jaws of the apparatus. The jaws move towards each other and crush the tablet. The apparatus records the force needed to crush the tablet with a precision of 1 Newton (1 N).
  • hardness of 100 N or more is desired, preferably hardness of 150 N or more.
  • Tablet hardness does not grow indefinitely, but normally increases to a certain plateau, and does not increase anymore with increased compression force.
  • the hardness and the content of the lubricant, e.g. magnesium stearate is linked to the dissolution profile.
  • the composition of the present disclosure can achieve comparable dissolution profile of the FDA approved capsules. Therefore, it is expected that the present composition may achieve at least the same therapeutic effect as currently approved Ceritinib capsules.
  • the tablet comprising Ceritinib can be prepared by wet granulation.
  • the process of preparing the tablet comprises the steps of: a) Preparing granules comprising Ceritinib and a binder by wet granulation, b) mixing the granules with at least one other pharmaceutical excipient to obtain a mixture, and c) compressing the mixture in the tablet.
  • all excipients can be wet granulated with the active and compressed in the tablet.
  • the steps a), b) and c) of the process can be employed as described above.
  • Mixing in step b) can be carried out in the absence of any granulation liquid, so that the blend obtained is substantially dry. This can help reduce the sticking and picking problem of Ceritinib.
  • the process can further comprise the steps of calibrating the granule size, depositing a lubricant on the surfaces of a pressing tool, particularly tableting machine punches, and/or coating a tablet.
  • Calibrating the granule size can be achieved by sieving. Extra fine particles and bulky granules can be removed to improve flowability of the granules in bulk.
  • Coating can be film coating and can be obtained by spraying the solution or a suspension of a coating polymer on the tablet cores.
  • the coating solution or suspension comprises further excipients such as a colorant or plasticizer.
  • the coating can take place for example in a coating drum or a wurster apparatus.
  • the process is suited to prepare tablets comprising at least 150 and up to 750 mg Ceritinib.
  • the dose of Ceritinib is at least 150 mg and up to 375 mg, including 300 mg.
  • the Ceritinib dose is 150 mg.
  • the dose is 375 mg.
  • the dose is 300 mg.
  • Magnesium stearate improves the processability and can be added to the pharmaceutical mixture for tableting in at least 0.5 and up to 3 weight percent based on the total weight of the mixture, at least 1 and up to 2 weight percent, preferably at least 1.3 and up to 1.7 weight percent, particularly 1.5 weight percent of magnesium stearate based on the total weight of the mixture.
  • the process is suitable to yield tablets with high drug load.
  • Tablets with even 70 weight percent of active ingredient can be prepared. Also other percent ranges of the active can be easily obtained, for example the tablet with at least 40 and up to 70 weight percent of Ceritinib, preferably at least 45 or 50 and up to 70 weight percent, more preferably at least 55 and up to 65 weight percent, particularly 60 weight percent of Ceritinib based on the total weight of the uncoated tablet.
  • a lubricant e.g. magnesium stearate
  • the process leads to a tablet with hardness of at least 45 N for a tablet comprising at least 150 mg Ceritinib and less than 300 mg.
  • the hardness of said tablet can be between 50 and 82 N, preferably between 58 and 72 N, most preferably is between 64 and 71N.
  • Tablets with larger dose e.g. with doses of 300 mg or more, e.g. up to 750 mg, particularly 375 mg, should have harness of 100 N or more, preferably of 150 N or more.
  • the pharmaceutical composition or the tablet according to the present disclosure can be used as a medicine. Ceritinib is primarily indicated for the treatment of patients with a proliferative disease.
  • the proliferative disease according to the present disclosure can be cancer.
  • the cancer includes lung cancer.
  • the proliferative disease is a non-small cell lung cancer, particularly is.
  • the descriptor ALK-positive refers to anaplastic lymphoma kinase (ALK) being mutated in a way that leads to activation or higher activity of ALK compared to the activity of the wild type ALK or ALK in a healthy control.
  • the pharmaceutical composition or the tablet can be used to treat ALK-positive non-small cell lung cancer, wherein the cancer has progressed on or is intolerant to crizotinib.
  • the pharmaceutical composition or the tablet can be used for the manufacture of the medicament, particularly for the treatment of the aforementioned diseases.
  • the method of treating a patient in need of ceritinib, the method comprising administering the pharmaceutical composition or the tablet according of the present disclosure is also contemplated herein.
  • Granulator Top or bottom driven High shear mixer.
  • Tableting machine Compaction simulator/Excentric tableting machine, rotary tableting machine
  • Roller compactor Cantilevered roll design and feature a vertical tapered deed screw system
  • Dissolution apparatus USP II Dissolution apparatus
  • Roller compaction approach (dry granulation) shown in example 2 was done by blending LDK378 drug substance, Mannitol, and a portion of Cellulose microcrystalline, Crospovidone, Colloidal silica and Mg-stearate as an inner phase and dry compacting it, while another portion of Cellulose microcrystalline, Crospovidone, Colloidal silicon dioxide and Mg-stearate was added as the extra-granular phase, mixed with the granules and compressed.
  • wet granulation (example 3) was done by using LDK378 drug substance, Mannitol, Hypromellose and a portion of Cellulose microcrystalline and Croscarmellose Sodium as an inner phase, while using the rest of Cellulose microcrystalline, Croscarmellose-Sodium together with Colloidal silicon dioxide and Mg-stearate as an extra granular phase.
  • Hypromellose and povidone were selected for testing out of several binder types (starch based binders, povidone based binders, copovidone based binders, hypromellose based binders, hydroxypropylcellulose based binders and hydroxyethylcellulose based binders) (cf. examples 4 and 5 in table 2).
  • a binder for wet granulation can be added either in a dry state to the granulation mixture (granule phase) before the wet granulation is conducted with water or the binder can be dissolved in e.g.
  • the granulation mixture can consist of a drug substance and several excipients (e.g. filler, disintegrant and/or other excipients) which are granulated together with the applied binder (examples 4 and 5).
  • excipients e.g. filler, disintegrant and/or other excipients
  • examples 4 and 5 e.g. filler, disintegrant and/or other excipients
  • a specifically modified approach was taken, by which only the drug and the binder got wet granulated and represent an inner phase, whereas the remainder of pharmaceutical excipients was added afterwards as an outer phase (example 6).
  • this novel granulation process only drug substance (without any additional excipients) was granulated using dissolved povidone as the binder. The obtained drug substance granules were blended with the outer phase and compressed into tablets.
  • the choice of the binder type did not significantly improve the compressibility.
  • povidone did improve the friability.
  • a significant improvement of the compressibility was achieved by direct granulation of the LDK378 drug substance with dissolved povidone. After drying of the wet granules, all other excipients were added as the outer phase and compressed into tablets. The tablet hardness during compression significantly improved, although a similar or lower compression force was used, which was an unexpected improvement.
  • This good compressibility of LDK378 film-coated tablets was achieved by using the novel granulation technique, whereby solely drug substance and povidone as the binder were granulated. The tablets disintegrated within 15 minutes, which meet the requirement for immediate release tablets.
  • the tablets were prepared by the specific wet granulation process comparable to Example 6. Soluble filler mannitol in the outer phase was replaced by higher amount of microcrystalline cellulose and an additional dry binder was added to the outer phase. Two different dry binders, Hydroxypropyl Cellulose Low-substituted and Copovidone were evaluated at 5% level in the outer phase (see example 8 and 9). The friability went from 0.65% to 0.11% when using Hydroxypropyl Cellulose Low-substituted. Overall, these formulation development activities led to reduced tablet friability and further increase compressibility.
  • the tablets were prepared by the specific wet granulation process comparable to Example 6, with only Ceritinib (LDK378) and the binder being granulated and making the inner phase.
  • the sticky nature of LDK378 drug substance was observed.
  • Trials on direct compression and roller compaction (see example 1 and 2) failed due to strong sticking during manufacturing. Solely by implementing wet granulation technology, the sticking tendency was reduced to a minimum (see examples 3A and 3B).
  • the implementation of the novel granulation technology whereby drug substance is directly granulated with a binder to form the inner phase of granules, further reduced observed stickiness to a minimum. Nevertheless, the amount of lubricant can further reduce the stickiness during compression.
  • Example 11 Example 12 (WG - 60% DL, (WG - 60% DL, (WG - 60% DL, 1.0% lubricant) 1.3% lubricant) 1.5% lubricant) Quantity [%] Quantity [%] Quantity [%] Ingredient (Pharm.
  • Examples 10-12 demonstrate the need for adequate lubrication of the composition. Above lubrication levels of 1.3%, the sticking is reduced to a minimum and at 1.5% no sticking was observed. However, examples 10-12 also demonstrate the impact of high lubrication on the compressibility and friability, whereby both, the compressibility as well as the friability can be negatively impacted by higher amounts of a lubricant. As shown in example 12, a stable manufacturing process was achieved by the novel granulation technology together with the adapted outer phase and the optimized lubricant concentration, leading to a formulation and process resulting in a tablet with suitable compressibility and friability, while no sticking occurs during manufacturing.
  • LDK378 150 mg tablet (optionally film-coated) is as follows:
  • step 3 Add povidone solution from step 2 to the granulator for wetting and kneading to prepare the granules.
  • step 4 Dry the obtained granules from step 3 in a fluid bed dryer.
  • the sieve can have mesh with openings of 0.8 mm.
  • coating premixes e.g. HPMC and non-functional color coating
  • compositions are non-limitative and illustrate the invention, including all strength of LDK378, which is 150 mg, 300 mg and 375 mg. Especially the 375 mg strength demonstrate the benefit of the current formulation for patient, since the pill burden is reduced from 5 capsules of 23.3 mm size (capsule size 00) to 2 tablets of 17 mm size per day.
  • Example 14 Example 15 (WG - 60% DL, (WG - 60% DL, (WG - 60% DL, 150 MG strength) 300 MG strength) 375 MG strength) Quantity [%] Quantity [%] Quantity [%] Ingredient (Pharm.
  • Example 16 150 MG Example 17 300 MG Example 18 375 MG film coated tablet film coated tablet film coated tablet Quantity [mg] Quantity [mg] Quantity [%] Quantity [mg] Quantity [%] Ingredients per FCT per FCT per FCT per FCT per FCT per FCT LDK378 drug substance 150.0 57.7 300.0 58.1 375.0 58.2 Povidone 10.0 3.8 20.0 3.9 25.0 3.9 Purified Water qs — qs — qs — Inner Phase (granulate) 160.0 61.5 320.0 62.0 400.0 62.1 Cellulose, Microcrystalline 62.5 24.0 125.0 24.2 156.25 24.3 Croscarmellose Sodium 10.0 3.8 20.0 3.9 25.0 3.9 Hydroxypropyl Cellulose 12.5 4.8 25.0 4.8 31.25 4.9 Low-substituted Colloidal Silicon Dioxide 1.25 0.5 2.5 0.5 3.12 0.5 Magnesium Stearate 3.75 1.4 7.5 1.5 9.38

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
US15/313,367 2014-05-29 2015-05-27 Ceritinib formulation Abandoned US20170112834A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/313,367 US20170112834A1 (en) 2014-05-29 2015-05-27 Ceritinib formulation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004359P 2014-05-29 2014-05-29
US15/313,367 US20170112834A1 (en) 2014-05-29 2015-05-27 Ceritinib formulation
PCT/IB2015/053966 WO2015181739A1 (en) 2014-05-29 2015-05-27 Ceritinib formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/053966 A-371-Of-International WO2015181739A1 (en) 2014-05-29 2015-05-27 Ceritinib formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/142,263 Continuation US20190022095A1 (en) 2014-05-29 2018-09-26 Ceritinib formulation

Publications (1)

Publication Number Publication Date
US20170112834A1 true US20170112834A1 (en) 2017-04-27

Family

ID=53298568

Family Applications (4)

Application Number Title Priority Date Filing Date
US15/313,367 Abandoned US20170112834A1 (en) 2014-05-29 2015-05-27 Ceritinib formulation
US16/142,263 Abandoned US20190022095A1 (en) 2014-05-29 2018-09-26 Ceritinib formulation
US16/571,229 Active US11000523B2 (en) 2014-05-29 2019-09-16 Ceritinib formulation
US17/168,265 Active 2037-12-13 US12357630B2 (en) 2014-05-29 2021-02-05 Ceritinib formulation

Family Applications After (3)

Application Number Title Priority Date Filing Date
US16/142,263 Abandoned US20190022095A1 (en) 2014-05-29 2018-09-26 Ceritinib formulation
US16/571,229 Active US11000523B2 (en) 2014-05-29 2019-09-16 Ceritinib formulation
US17/168,265 Active 2037-12-13 US12357630B2 (en) 2014-05-29 2021-02-05 Ceritinib formulation

Country Status (27)

Country Link
US (4) US20170112834A1 (enrdf_load_stackoverflow)
EP (1) EP3148513B1 (enrdf_load_stackoverflow)
JP (3) JP6679578B2 (enrdf_load_stackoverflow)
KR (1) KR20170008239A (enrdf_load_stackoverflow)
CN (1) CN106456640B (enrdf_load_stackoverflow)
AR (1) AR100625A1 (enrdf_load_stackoverflow)
AU (3) AU2015265470A1 (enrdf_load_stackoverflow)
BR (1) BR112016027580A8 (enrdf_load_stackoverflow)
CA (1) CA2948291A1 (enrdf_load_stackoverflow)
CL (1) CL2016003047A1 (enrdf_load_stackoverflow)
DK (1) DK3148513T3 (enrdf_load_stackoverflow)
EA (1) EA036922B1 (enrdf_load_stackoverflow)
EC (1) ECSP16096826A (enrdf_load_stackoverflow)
ES (1) ES2792574T3 (enrdf_load_stackoverflow)
HU (1) HUE048950T2 (enrdf_load_stackoverflow)
IL (1) IL248835B (enrdf_load_stackoverflow)
MX (1) MX373624B (enrdf_load_stackoverflow)
PE (1) PE20170313A1 (enrdf_load_stackoverflow)
PH (1) PH12016502272A1 (enrdf_load_stackoverflow)
PL (1) PL3148513T3 (enrdf_load_stackoverflow)
PT (1) PT3148513T (enrdf_load_stackoverflow)
SG (1) SG11201609208UA (enrdf_load_stackoverflow)
SI (1) SI3148513T1 (enrdf_load_stackoverflow)
TN (1) TN2016000484A1 (enrdf_load_stackoverflow)
TW (1) TWI721946B (enrdf_load_stackoverflow)
UY (1) UY36140A (enrdf_load_stackoverflow)
WO (1) WO2015181739A1 (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3148513B1 (en) 2014-05-29 2020-02-26 Novartis AG Ceritinib formulation
CN106176752B (zh) * 2015-05-07 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 色瑞替尼药物组合物
CN109381440A (zh) * 2018-11-15 2019-02-26 威海贯标信息科技有限公司 一种艾乐替尼组合物
CN113244236B (zh) * 2021-06-01 2023-02-03 上海市第一人民医院 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0708592A2 (pt) 2006-03-06 2011-06-07 Wyeth Corp formulação farmacêutica, tablete, processo para peparar um formulação farmacêutica, produto, e, processo para produzir um tablete
US20080175901A1 (en) 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20090239920A1 (en) 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
MY148427A (en) * 2006-12-08 2013-04-30 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
SI2334202T1 (sl) * 2008-09-04 2012-04-30 Cargill Inc Tabletiranje eritritola
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
BR112012003631A2 (pt) 2009-08-18 2015-09-01 Gargill Inc "produção de comprimidos de eritritol e isomalte."
ES2836952T3 (es) 2010-05-11 2021-06-28 Mitsubishi Tanabe Pharma Corp Comprimidos que contienen canagliflozina
RU2013115388A (ru) 2010-09-07 2014-10-20 Карджилл, Инкорпорейтед Смесь отвержденных сахарных спиртов
EP3148513B1 (en) 2014-05-29 2020-02-26 Novartis AG Ceritinib formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Goodman and Gilman’s The Pharmacological Basis of Therapeutics (Tenth Edition (2001), McGraw Hill, Chapter I, pages 3-29 *

Also Published As

Publication number Publication date
BR112016027580A2 (pt) 2017-08-15
JP7084955B2 (ja) 2022-06-15
JP2022078236A (ja) 2022-05-24
SI3148513T1 (sl) 2020-07-31
AU2015265470A1 (en) 2016-11-24
JP2020114834A (ja) 2020-07-30
JP6679578B2 (ja) 2020-04-15
SG11201609208UA (en) 2016-12-29
PH12016502272A1 (en) 2017-02-06
ECSP16096826A (es) 2018-04-30
EA201692310A1 (ru) 2017-04-28
AU2018203007B2 (en) 2019-07-18
HUE048950T2 (hu) 2020-09-28
TW201613580A (en) 2016-04-16
KR20170008239A (ko) 2017-01-23
JP2017520619A (ja) 2017-07-27
MX373624B (es) 2020-05-22
TN2016000484A1 (en) 2018-04-04
TWI721946B (zh) 2021-03-21
US20210154194A1 (en) 2021-05-27
AU2019232937B2 (en) 2020-10-15
CN106456640B (zh) 2021-05-14
IL248835A0 (en) 2017-01-31
EP3148513B1 (en) 2020-02-26
MX2016015736A (es) 2017-03-16
PL3148513T3 (pl) 2020-08-24
WO2015181739A1 (en) 2015-12-03
US12357630B2 (en) 2025-07-15
UY36140A (es) 2016-01-08
US20200009141A1 (en) 2020-01-09
PT3148513T (pt) 2020-05-27
EA036922B1 (ru) 2021-01-15
BR112016027580A8 (pt) 2021-06-29
EP3148513A1 (en) 2017-04-05
PE20170313A1 (es) 2017-04-18
ES2792574T3 (es) 2020-11-11
AU2019232937A1 (en) 2019-10-10
AR100625A1 (es) 2016-10-19
AU2018203007A1 (en) 2018-05-17
CA2948291A1 (en) 2015-12-03
CN106456640A (zh) 2017-02-22
US20190022095A1 (en) 2019-01-24
US11000523B2 (en) 2021-05-11
IL248835B (en) 2020-05-31
CL2016003047A1 (es) 2017-04-07
DK3148513T3 (da) 2020-05-25

Similar Documents

Publication Publication Date Title
US12357630B2 (en) Ceritinib formulation
KR100728846B1 (ko) 약물 함유량이 높은 정제
EP2974720B1 (en) Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration
CN106943355B (zh) 药物组合物
US10207002B2 (en) Sustained release formulation and tablets prepared therefrom
KR101977785B1 (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
KR20180042115A (ko) 레날리도마이드의 경구용 정제 조성물
JP2025013941A (ja) ダロルタミドの医薬組成物
EP4260910A2 (en) Pharmaceutical preparation
US20160022661A1 (en) Dosage Form Comprising Crizotinib
HK1229715A1 (en) Ceritinib formulation
HK1229715B (en) Ceritinib formulation
CN104000821B (zh) 含有替米沙坦和苯磺酸氨氯地平的口服双层片剂及其制备方法
OA19661A (en) Tablets comprising 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-YL) Pyridin-3-YL) Methoxy) Benzaldehyde.
EA041427B1 (ru) Фармацевтические лекарственные формы

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS PHARMA AG;REEL/FRAME:040403/0880

Effective date: 20140610

Owner name: NOVARTIS PHARMA AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BREULLES, SEBASTIAN;ENSSLIN, SIMON;REEL/FRAME:040403/0817

Effective date: 20140605

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION